Skip to main content

Farxiga Dosage

Generic name: DAPAGLIFLOZIN PROPANEDIOL 5mg
Dosage form: tablet, film coated
Drug class: SGLT-2 inhibitors

Medically reviewed by Drugs.com. Last updated on Jan 15, 2024.

Prior to Initiation of FARXIGA

Assess renal function prior to initiation of FARXIGA therapy and then as clinically indicated [see Warnings and Precautions (5.2)].

Assess volume status. In patients with volume depletion, correct this condition before initiating FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5, 8.6)].

Recommended Dosage

See Table 1 for dosage recommendations based on estimated glomerular filtration rate (eGFR).

Table 1: Recommended Dosage
*
FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m2. FARXIGA is likely to be ineffective in this setting based upon its mechanism of action.

eGFR
(mL/min/1.73 m2)

Recommended Dose

eGFR 45 or greater

To improve glycemic control, the recommended starting dose is 5 mg orally once daily. Dose can be increased to 10 mg orally once daily for additional glycemic control*.

For all other indications, the recommended starting dose is 10 mg orally once daily.

eGFR 25 to less than 45

10 mg orally once daily*.

eGFR less than 25

Initiation is not recommended; however, patients may continue 10 mg orally once daily to reduce the risk of eGFR decline, ESKD, CV death and hHF.

hHF: hospitalization for heart failure, CV: Cardiovascular, ESKD: End Stage Kidney Disease.

2.3 Temporary Interruption for Surgery

Withhold FARXIGA for at least 3 days, if possible, prior to major surgery or procedures associated with prolonged fasting. Resume FARXIGA when the patient is clinically stable and has resumed oral intake [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.